2022. Second-generation androgen receptor inhibitors in therapy of non-metastatic castration resistant prostate cancer: role of safety profile and effect on quality of life. Voprosy onkologii. 67, 2 (May 2022), 217–226. DOI:https://doi.org/10.37469/0507-3758-2021-67-2-217-226.